Effect of pharmacogenetic polymorphisms on the pharmacokinetics and pharmacodynamics of rivaroxaban in elderly patients with non-valvular atrial fibrillation

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300074934

Enrollment

Unknown

Registered

2023-08-21

Start date

2023-08-20

Completion date

Unknown

Last updated

2023-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atrial fibrillation

Interventions

Case series:none

Eligibility

Sex/Gender

All

Age

65 Years to 120 Years

Inclusion criteria

Inclusion criteria: (1) age =65 years; (2) diagnosis of nonvalvular atrial fibrillation; (3) good medication adherence, taking rivaroxaban for more than 3 days as prescribed by the physician; and (4) voluntary enrollment in this trial and signing of an informed consent form.

Exclusion criteria

Exclusion criteria: (1) severe renal insufficiency (creatinine clearance =15 ml/min); (2) hepatic insufficiency (Child-Pugh score =7); (3) incomplete dosing information

Design outcomes

Primary

Measure	Time frame
bleeding events;thrombotic events;steady-state peak concentration;Steady state trough concentration;	—

Countries

China

Contacts

Public ContactJiale Chen

Jinhua Municipal Central Hospital

chenjiale0226@126.com+86 188 6756 4304

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026